The boom of copyright’s drug initially fueled significant growth in the medicinal sector, creating a perception of substantial returns. However, placing capital in companies primarily reliant on flagship drugs like Viagra presents significant challenges. Patent expiration has caused off-brand cha

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for blockbuster treatments and significant returns is certain, the as